OSE Immunotherapeutics announced the launch of the issuance by the Japanese Patent Office of the new patent class for the management of positive TL-memory reaction in HLA-A2 cancer treatments in Tedopi, a mixture of neoepitopes. Until 2035 this patent shall be secured.
Tedopi is a mixture of ten neo-epitopes, chosen and engineered for 5 tumor-associated antigens that elicit a specific immune response in patients with positive HLA-A2. In tandem with T-helping cells, memory T-cells identify and develop a particular cytotoxic reaction against at least one of these tumor-associated antigens produced by the tumor cells.
“This patent infringement family issued in Japan is further extending Tedopi patent protection and increasing our portfolio in resistant oncology. This approval further validates an early T lymphocytic memory response process in positive HLA-A2 patients that accounts for 45 percent of the population and involves all cancers. In fact, Tedopi is a leading commodity in a large demographic of patients with more than 1 million new cancer cases in Japan in 2018 and a growing market of oncologic medicines in that nation and around the globe, “said Alexis Peyroles, Chief Executive Officer, OSE Immunotherapeutics. OSE Immunotherapy.
Tedopi is now tested for HLA-A2 positive patients, after relapse from prior trials with inhibiting PD-1/PD-L1 control point, in a Phase 3 study identified as Atalante 1 in advanced non-small-cell lung cancer (NSCLC). Even with the improvement in treatment options lately, most NSCLC patients do not respond to enzyme management therapy, which poses a tremendous need for these patients to have an appropriate new alternative. By the end of Q1 2020, the findings of the first phase of this progressing study are awaited. In an active phase 2 study in adults with pancreatic cancer, Tedopi is also being tested.